Croughan Pete, Gee Rebekah E
A medical student at the University of California, San Francisco, School of Medicine, and previously served as policy director at the Louisiana Department of Health, where he worked on financing for graduate medical education, pharmaceutical policy, analyzing federal health reform efforts, and developing a statewide cancer strategy, and served as chief of staff for the department.
Secretary of the Louisiana Department of Health as well as an associate professor (currently on leave) at the Louisiana State University School of Medicine and School of Public Health in New Orleans, and an obstetrician-gynecologist and trained policy expert.
AMA J Ethics. 2019 Aug 1;21(8):E630-635. doi: 10.1001/amajethics.2019.630.
Hepatitis C poses public health and fiscal crises for state Medicaid programs trying to respond to this epidemic. Meager funding streams, a lack of negotiating power, and escalating pharmaceutical prices exacerbate the financial strain placed on these programs as they struggle to meet public health priorities. The Louisiana Department of Health has adopted a subscription model for hepatitis C treatment, but costly medications continue to challenge states' capacities to cover patients who need costly drugs.